Abstracts tagged "COVID-19"

Abstract Number: 1897 • ACR Convergence 2024
People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective
Shahdi Malakooti¹, Marc Abboud², Jennifer Murphy³, Nora Singer⁴ and Grace McComsey⁵, ¹MetroHealth at Case Western Reserve University, Cleveland, ²Saint Joseph Medical School, Beirut, Lebanon, ³University Hospitals, Cleveland, OH, ⁴MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁵University Hospitals at Case Western Reserve University, Cleveland
Background/Purpose: Post-Acute Sequelae of SARS-CoV-2 (PASC) include new or worsening of existing symptoms 3 months or more after SARS-CoV-2 infection. We have shown that vaccination…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…
Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Kaleb Michaud¹, Shreena Kamlesh Gandhi², Sofia Pedro³, Cassandra Calabrese⁴, Patti Katz⁵ and Leonard Calabrese⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Kansas University School of Medicine - Wichita, Wichita, KS, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Cleveland Clinic Foundation, Cleveland Heights, OH, ⁵UCSF, San Rafael, CA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…
Abstract Number: 1907 • ACR Convergence 2024
Community-Engaged Curriculum Development Using Racial Justice and Biomedical Lenses to Address COVID-19 Vaccine Hesitancy in Black Individuals with Rheumatologic Conditions
Eseosa Osaghae¹, Greta Sirek², Tonya Roberson³, Mia Chandler⁴, Ariel Childs⁵, Monica Crespo-Bosque⁶, Gina Curry⁷, Amar Dhand⁸, Mary Dollear⁹, Alice Eggleston¹⁰, Nnenna Ezeh², Dieufort Fleurissaint¹¹, Denice Garrett¹², Gail Granville¹³, Muriel Jean-Jacques¹, Elena Losina², Holly Milaeger¹, Lutfiyya Muhammad¹⁴, Mary Ann Nelson¹⁵, Chisa Nosamiefan¹⁶, Bisola Ojikutu¹⁷, Neil Pillai¹, Marie Jacques Toussaint¹⁸, Mary Beth Son¹⁹, Ana Valle², Jessica Williams²⁰, Michael York²¹, Karen Mancera-Cuevas²², Candace Feldman² and rosalind Ramsey-Goldman¹, ¹Northwestern University, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Governors State University College of Health and Human Services, University Park, IL, ⁴Boston Children’s Hospital, Boston, MA, ⁵Vital CxNs, Boston, MA, ⁶Boston Medical Center, Boston, MA, ⁷University of Chicago Pritzker School of Medicine, Chicago, IL, ⁸Brigham and Women’s Hospital, Boston, MA, ⁹Lupus Society of Illinois, Chicago, IL, ¹⁰Alliance Chicago, Chicago, IL, ¹¹True Alliance Center, Inc, Boston, MA, ¹²Action for Bridgeport Community Development, Inc., Bridgeport, CT, ¹³Women of Courage, Inc, Boston, MA, ¹⁴Northwestern Feinberg School of Medicine, Chicago, IL, ¹⁵Mission Hill Health Movement Inc, Roxbury, MA, ¹⁶The Labalaba Foundation for Lupus Awareness and Advocacy, South Weymouth, MA, ¹⁷Harvard Medical School, Brigham and Women’s Hospital, Boston Public Health Commission,, Boston, MA, ¹⁸True Alliance Center, Inc., Boston, MA, ¹⁹Boston Children's Hospital, Brookline, MA, ²⁰Emory School of Medicine, Atlanta, GA, ²¹Boston University, Boston, MA, ²²National Health Council, Washington, DC
Background/Purpose: Despite the efficacy of COVID-19 vaccines and the benefits for individuals with rheumatic conditions, racial inequities in uptake persist. We initiated a trial that…
Abstract Number: 0172 • ACR Convergence 2024
Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies
Brandon Levian¹, Charlotte Botz², Jason Chwa², Sophie Grove², Vignesh Ravi², Branden Ireifej³, daniel arkfeld⁴, Diana Hanna², Jenny Hu² and Binh Ngo², ¹Keck School of Medicine, Beverly Hills, CA, ²Keck School of Medicine, Los Angeles, ³LAGMC/Keck School of Medicine, Los Angeles, CA, ⁴Keck Medical Center of USC, RANCHO PALOS VERDES, CA
Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
Abstract Number: 1921 • ACR Convergence 2024
Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
Kari Falaas¹, Michael Schnaus², Margaret Singer³, Allison Hochstetler³, Pang Nhia Khang⁴, Katherine Schmiechen⁴ and Elie Gertner³, ¹University of Minnesota, Regions Hospital, Minneapolis, MN, ²University of Minnesota, Regions Hospital, Methodist Hospital, Minneapolis, ³University of Minnesota, Regions Hospital, Minneapolis, ⁴Regions Hospital, Minneapolis
Background/Purpose: Hyperuricemia is associated with an elevated risk of developing cardiovascular diseases, diabetes, chronic kidney disease, and metabolic syndromes. The Hmong population, in particular, has…
Abstract Number: 0173 • ACR Convergence 2024
Systemic Lupus Erythematosus Mortality—United States, 2018–2022
Danielle Dawson¹, Kurt Greenlund² and Kamil Barbour², ¹CDC, Atlanta, GA, ²CDC, Alpharetta, GA
Background/Purpose: Mortality due to cardiovascular disease, infections, and renal disease is elevated in people with systemic lupus erythematosus (SLE) compared with the general population, but…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1982 • ACR Convergence 2024
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Sarah Ifteqar¹, Mallak Zatreh², Aatif Syed¹, Xiangni Wu³, Asad Kabir⁴, John Foxworth⁵ and AMR EDREES⁶, ¹University of Missouri Kansas City, Kansas City, MO, ²3. Hutchinson Regional Medical Center, Hutchinson, Kansas, USA, Kansas City, ³UMKC, KANSAS CITY, MO, ⁴5. Pulmonary Critical Care, Mosaic Life Care Health System, St. Joseph, Missouri, USA, Kansas City, ⁵2. Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA, Kansas City, ⁶UMKC, Overland Park, KS
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus affect 3-5% of Americans and causes significant morbidity due to chronic…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 1017 • ACR Convergence 2024
Non-Adherence and Missed Appointments in Rheumatology: Pre and Post COVID-19 Pandemic Impact
Daniela Alejandra Salcedo-Soto¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Deynna Montserrat Lara Mendez⁴, Diana Elsa Flores-Alvarado⁵, Jorge Esquivel-Valerio⁶, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatic diseases (RDs) require consistent management with disease-modifying antirheumatic drugs (DMARDs) and regular medical follow-up. However, non-adherence to medication and unattended appointments are common…
Abstract Number: 2025 • ACR Convergence 2024
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications
Norman Gaylis¹, Odence DeLaRosa², Joanne Sagliani¹ and Andrew Holman³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Arthritis & Rheumatic Disease Specialties., Aventura, FL, ³Inmedix, Inc, Seattle, WA
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with COVID-19 develop some post-COVID symptoms, i.e. post-acute sequalae of SARS-CoV-2 (PASC)…
Abstract Number: 0208 • ACR Convergence 2024
Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study
Hajar Elhani¹, abderrahim majjad², Leila Taoubane³, Najlae Elouardi¹, Hamza Toufik⁴ and AHMED BEZZA⁵, ¹Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, Morocco, ²military hospital of rabat, rabat, Morocco, ³Mohamed V Military Training Hospital, Rheumatology, Rabat, Morocco, Rabat, ⁴Mohamed V Military Training Hospital, Rheumatology, Rabat, Rabat, Morocco, ⁵Hopital Militaire Med V RABAT, Rabat, Morocco
Background/Purpose: The COVID-19 pandemic has heightened concerns regarding the susceptibility of immunocompromised patients, particularly those with autoimmune diseases like rheumatoid arthritis (RA). Early recommendations from…
Abstract Number: 1104 • ACR Convergence 2024
Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era
Carmen Lasa Teja¹, Amparo Sánchez-López², María Enriqueta Peiró³, Mónica Renuncio-García⁴, Adrián Martín-Gutiérrez⁵, Carmen Secada Gómez⁶, Juan Irure-Ventura⁷, Marcos Lopez-Hoyos⁸ and Ricardo Blanco-Alonso⁹, ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Immunology, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁸Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: There have been increasing reports of cutaneous manifestations during COVID‐19 pandemic. An increase in awareness by physicians made them to increase the number of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].